

SUPPORTING INFECTIOUS DISEASE RESEARCH

Product Information Sheet for NR-13550

Staphylococcus aureus, Strain SU-5

Catalog No. NR-13550

For research use only. Not for human use.

Contributor:

Kristien Mortelmans, Ph.D., Director, Microbiology Program, Biosciences Division, SRI International, Menlo Park, California

Manufacturer:

BEI Resources

Product Description:

Bacteria Classification: Staphylococcaceae, Staphylococcus

Species: Staphylococcus aureus

Strain: SU-5

Original Source: Staphylococcus aureus (S. aureus), strain SU-5 was isolated in October 2005 from a Stanford Hospital patient in Palo Alto, California, U.S.A.¹

Comments: S. aureus, strain SU-5 is a hospital-acquired (HA) methicillin-resistant S. aureus (MRSA) strain based on multilocus sequence typing and antibiogram results. Strain SU-5 is sensitive to vancomycin and resistant to oxacillin, clindamycin and ciprofloxacin. Note: Methicillin is no longer clinically used, however, the term methicillin-resistant Staphylococcus aureus (MRSA) continues to be used to describe Staphylococcus aureus strains resistant to all penicillins.

S. aureus is a Gram-positive, cluster-forming coccus that normally inhabits human nasal passages, skin and mucus membranes. It is also a human pathogen and causes a variety of pus-forming infections as well as food-poisoning and toxic shock syndrome. In 1961, two years after the introduction of methicillin, a penicillinase-resistant penicillin, S. aureus developed methicillin-resistance due to acquisition of the mecA gene. For the last forty-five years HA MRSA strains have disseminated worldwide. More recently, MRSA strains have been isolated that are not hospital acquired and are referred to as community-associated (CA) MRSA. CA-MRSA strains differ phenotypically and genotypically from HA-MRSA strains and they are more frequently recovered from skin and soft tissue sources rather than post-operative wounds.^{2,3}

Material Provided:

Each vial contains approximately 0.5 mL of bacterial culture in 0.5X Brain Heart Infusion Broth supplemented with 10% glycerol.

<u>Note</u>: If homogeneity is required for your intended use, please purify prior to initiating work.

Packaging/Storage:

NR-13550 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -80°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:

Media:

Brain Heart Infusion Broth or equivalent Brain Heart Infusion Agar or equivalent

Incubation:

Temperature: 37°C Atmosphere: Aerobic

Propagation:

- 1. Keep vial frozen until ready for use, then thaw.
- 2. Transfer the entire thawed aliquot into a single tube of broth
- 3. Use several drops of the suspension to inoculate an agar slant and/or plate.
- Incubate the tube, slant and/or plate at 37°C for 24 hours.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: *Staphylococcus aureus*, Strain SU-5, NR-13550."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898



Product Information Sheet for NR-13550

SUPPORTING INFECTIOUS DISEASE RESEARCH

ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, noncommercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

- 1. Dr. Kristien Mortelmans, personal communication.
- Deurenberg, R. H. and E. E. Stobberingh. "The Evolution of Staphylococcus aureus." <u>Infect. Genet. Evol.</u> 8 (2008): 747-763. PubMed: 18718557.
- 3. Davis, S. L., et al. "Epidemiology and Outcomes of Community-Associated Methicillin-Resistant Staphylococcus aureus Infection." J. Clin. Microbiol. 45 (2007): 1705-1711. PubMed: 17392441.

ATCC[®] is a trademark of the American Type Culture Collection.

E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898